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Abstract 
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Introduction: Survival rates in pediatric leukemia have greatly improved in the last 
decades but still a substantial number of patients will relapse and die. New agents are 
necessary to overcome the limitations of conventional chemotherapy and hematopoietic 
stem cell transplantation and to reduce their undesirable long-term toxicities. The 
identification of driving molecular alterations of leukemogenesis in subsets of patients 
will allow the incorporation of new-targeted therapies.  
Areas covered: In this article the authors present a detailed review of the most recent 
advances in targeted therapies for pediatric leukemias. A comprehensive description of 
the biological background, adult data and early clinical trials in pediatrics is provided.  
Expert opinion: Clinical trials are the way to evaluate new agents in pediatric cancer. 
The development of new drugs in pediatric leukemia must be preceded by a solid 
biological rationale. Agents in development exploit all possible vulnerabilities of 
leukemic cells. Drugs targeting cell surface antigens, intracellular signaling pathways 
and cell cycle inhibitors or epigenetic regulators are most prominent. Major advances 
have occurred thanks to new developments in engineering leading to optimized 
molecules such as anti-CD19 bi-specific T-cell engagers (e.g. blinatumomab) and 
antibody-drug conjugates. The integration of new-targeted therapies in pediatric 
chemotherapy-based regimens will lead to improved outcomes.     
 
Abbreviations  
Term Abbreviation 
Accelerated phase AP 
Acute lymphoblastic leukemia  ALL 
Acute myeloid leukemia AML 
Acute promyelocytic leukemia APL 
Adverse event AE 
Antibody-drug conjugate ADC 
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All-trans retinoic acid ATRA 
Azacitidine AzaC 
Berlin-Frankfurt-Münster BFM 
bi-specific T-cell engager BITE 
Bis in die (Twice daily) BID 
Blastic phase BP 
Burkitt lymphoma BL 
Central nervous system CNS 
Cerebrospinal fluid CSF 
Children Oncology Group COG 
Chimeric antigen receptor T  CAR-T 
Chronic lymphocytic leukemia CLL 
Chronic myeloid leukemia  CML 
Chronic phase CP 
Complete remission CR 
Complete remission with partial hematologic recovery  CRh 
Complete cytogenetic response  CCyR 
Cytokine release syndrome CRS 
Down syndrome  DS 
DNA methyltransferase DNMT 
International Berlin-Frankfurt-Münster Study Group iBFM-SG 
European Medicines Agency EMA 
Experimental Cancer Medicine Centre ECMC 
Event-free survival EFS 
Gemtuzumab-ozogamicin GO 
Hematopoietic stem cell transplantation HSCT 
Innovative Therapies for Children with Cancer ITCC 
Internal tandem duplication ITD 
Intravenous  IV 
Juvenile myelomonocytic leukemia JMML 
Lymphoblastic lymphoma LL 
Major cytogenetic response MCyR 
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Major histocompatibility complex MHC 
Major molecular response MMR 
Maximum tolerated dose MTD 
Minimal residual disease MRD 
Mitogen-activated protein kinase MAPK 
Mixed lineage leukemia MLL 
Mixed lineage leukemia rearranged MLLr 
Monoclonal antibody mAb 
Monomethyl auristatin F MMAF 
Myelodysplastic syndrome MDS 
Once daily OD 
Overall survival OS 
Pediatric Preclinical Testing Program PPTP 
Pharmacokinetics PK 
Polo-Like kinase 1 PlK1 
Progression-free survival PFS 
Recommended phase II dose RP2D 
Relapse-free survival RFS 
Rhabdomyosarcoma RMS 
Stable disease SD 
Therapeutic Advances in Childhood Leukemia  TACL  
Therapeutically Applicable Research to Generate Effective 
Treatments 
TARGET 
Tyrosine kinase domain TKD 
Tyrosine-kinase inhibitor TKI 
United Kingdom UK 
United States US 
Veno-occlusive disease VOD 
Wild-type WT 
 
 
Article highlights  
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- Leukemia is the most frequent type of cancer in children. Survival rates have 
improved in the last decades but still a substantial number of patients will 
succumb to their disease. New agents are necessary to overcome the therapeutic 
imitations of conventional chemotherapy and hematopoietic stem cell 
transplantation and to reduce their long-term toxicity.  
- Pediatric research platforms for the identification of molecular alterations and 
novel targeted therapies have been developed, such as the Pediatric Pre-clinical 
Testing Program and the Therapeutically Applicable Research to Generate 
Effective Treatments project in the United States or the Innovative Therapies for 
Children with Cancer Consortium in Europe. A close collaboration between 
pharma, regulators and academic groups is necessary to incorporate these 
therapies into clinical practice.  
- New agents have been developed to target pathogenic molecular alterations at 
different cell levels: cell surface receptors, tyrosine-kinases, signaling pathways 
and the cell cycle. Immunotherapy in leukemia is key and new promising agents 
are being developed such as antibodies or CAR-T cells.  
- The introduction of targeted agents in particular subsets of children with 
leukemia harboring individual molecular alterations has radically changed their 
outcome, such as BCR-ABL fusion gene in chronic myeloid leukemia and Ph+ 
acute lymphoblastic leukemia. The identification of driving targetable molecular 
alterations in clonal leukemic cells will allow individualizing treatments while 
sparing patients of undesirable side effects.  
 
1. Introduction  
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Leukemia is the most common type of cancer in children [1]. 90-95% of those are acute 
leukemias. Acute lymphoblastic leukemia (ALL) is the most frequent (75-80%), 
followed by acute myeloid leukemia (AML) (20%) [1]. Less frequent are chronic 
myeloid leukemia (CML) and juvenile myelomonocytic leukemia (JMML) [1].  
The optimization in the use of existing conventional chemotherapeutic anti-leukemic 
agents together with improvements in risk-group stratification and supportive care have 
led to a significant increase in cure rates. Five-year event free survival (EFS) in 
pediatric ALL has increased from less than 10% in earlier efforts to more than 80% with 
current front-line regimens [2]. With very few exceptions, the drugs used today were 
available by the late 1960s. This improvement has been largely achieved as a result of 
international collaborative efforts through clinical trials [3]. In AML five-year survival 
rates reach up to 76% [4].  
Nonetheless, it seems that further intensification of treatment beyond the current 
standards is now maximized, and improvements in outcome have plateaued over the 
past decade [5]. Still, a substantial number of these patients will not be cured, and for 
those who survive long-term toxicities are of major importance [6].  Current efforts 
focus in particular clusters of patients with high-risk molecular or cytogenetic features, 
infants and relapsed or refractory leukemias [3].  
Molecular targeted agents have been developed in recent years in adult oncology, 
aiming at pathways that function predominantly in leukemic cells, ideally with absent or 
minimal function in healthy tissues. Such pathways may be initiated by cell surface 
receptors (CD33, CD22), specific intracellular kinases (FLT-3; BCR-ABL); proteins 
regulating cell death (BCL-2 family), and modulators of gene function [7]. However, in 
pediatric leukemia no other targeted agents have reached clinical practice besides 
tyrosine kinase inhibitors (TKI) in BCR-ABL rearranged ALL and CML.  
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The development of new agents in pediatrics virtually always lags behind that of the 
adults. Some reasons are: i) The success of frontline and even second line treatments 
results in a decreased number of children potentially able to participate in phase I-II 
trials; ii) The relatively small market of pediatric oncology does not provide the 
financial incentives for companies to actively pursue pediatric oncology drugs [8]; iii) 
Cancer biology in children is different from that of the adults in some diseases [9]; iv) 
Scarcity of preclinical pediatric models that allow to test broad-spectrum agents or 
histotype-specific activity against childhood cancers; v) Lack of incentives to groups 
developing new agents against specific pediatric targets [10]. Pure pediatric research 
platforms for the identification of molecular alterations and novel targeted therapies 
have been developed, such as the Pediatric Preclinical Testing Program (PPTP [11]; 
www.ncipptc.org)and the Therapeutically Applicable Research to Generate Effective 
Treatments project (TARGET [12]; target.nci.nih.gov) in the United States (US) and the 
Innovative Therapies for Children with Cancer (ITCC) consortium in Europe. These 
platforms are able to identify new targets and drugs that can be taken into clinic in 
collaboration with pharma and academic groups like the Therapeutic Advances in 
Childhood Leukemia (TACL), Children´s Oncology Group (COG), International 
Berlin-Frankfurt-Münster Study Group (iBFM-SG) or IntReALL.  
In this manuscript we will review the progress made in the development of targeted 
agents in pediatric leukemia. Drugs selected for discussion have been chosen based on 
their pre-clinical data, mode of action, relevancy in pediatric leukemias and current 
degree of development (Figures 1 and 2). Table 1 shows active and near future clinical 
trials with novel agents. A critical summary highlighting those agents with most 
prominent results is provided in the Expert Opinion section.  
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2. Cell surface antigens: Immune strategies 
This section summarizes most recent developments of agents targeting cell surface 
antigens of leukemic blasts, which exert a direct cytotoxic effect or trigger an indirect 
immune response.  
 
2.1. Chimeric antigen receptors 
First generation chimeric antigen receptors (CARs) are hybrid receptors that comprise a 
ligand for a cell-surface molecule, usually a single-chain variable fragment from a 
monoclonal antibody (mAb) or an antigen-binding fragment, which is fused to signaling 
domains redirecting T-cell function [13]. Second and third generation CARs incorporate 
additional domains to supply co-stimulatory signals enhancing T-cell toxicity [13].  
CD19 CAR-T cells have yielded impressive results in adult chronic lymphocytic 
leukemia  (CLL) with an overall response rate in the phase I trial approaching 60% in a 
heavily pretreated population [14].  
In children, two landmark early trials have shown exciting results in B-ALL creating 
major enthusiasm and social and media interest [15]. In pediatric trials, complete 
response (CR) rates ranged from 70 % to 90% [16, 17] and minimal residual disease 
(MRD) negativity rates of around 85% among those who achieved CR. In the Lee 
study, of those MRD negative patients, ten were able to proceed to hematopoietic stem 
cell transplantation (HSCT) and were still alive at last follow-up [17]. Interestingly, 
patients with central nervous system (CNS) disease cleared cerebrospinal fluid (CSF) 
blasts after treatment [16, 17] and no CNS relapses were observed [16]. Importantly, the 
feasibility rate of producing CD19 CAR-T cells was high (90%) [17]. The toxicity 
profile was mainly represented by the cytokine release syndrome (CRS) and 
hematological toxicities related to the lympho-depleting regimen.  
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A phase II trial of CD22 CAR-T cells is open for pediatric patients with 
relapsed/refractory CD22-expressing B cell malignancies (NCT02315612).  
 
2.2 CD20 directed therapy  
The surface antigen CD20 is present in 100% of children and adolescents with Burkitt 
lymphoma (BL) and 40% with B-ALL [18]. CD20 influences cell cycle progression and 
differentiation by modulating levels of proapotosis proteins and activation of surviving 
pathways [19].  
The most consolidated agent in this group is the chimeric mAb rituximab. Despite being 
widely used in adults and children, it still does not have a specific label for pediatric 
use. It has been used in combination with the hyper-CVAD regimen, as CD20 
expression had been associated with higher relapse rates in adults with the novo B-cell 
ALL [20]. This combination significantly improved survival in adolescents and young 
adults with newly diagnosed CD20 B-ALL when compared with chemotherapy alone 
(3-year overall survival (OS) 75% Vs 47%) [19]. In pediatric high-risk B-mature acute 
leukemia and BL, addition of rituximab to conventional chemotherapy significantly 
improved their outcome: 1-year EFS was 94.2% Vs 81.5% for those not receiving 
rituximab [21]. 
Ofatumumab targets a different epitope than rituximab. In adults with CD20 ALL, 
ofatumumab was added to the hyper-CVAD regimen. The 1-year PFS and OS were 
91% [22]. Most common grade 3 toxic events were hepatic, thrombosis and neuropathy. 
One trial is currently evaluating ofatumumab in newly diagnosed or first relapse B-cell 
ALL or lymphoblastic lymphoma (LL) children and adolescents with augmented BFM 
chemotherapy (NCT02419469).  
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2.3  CD19 directed therapy  
CD19 is expressed ubiquitously on B cells from the pro/pre B-cell stage to mature B-
cells and their malignant counterparts [23]. CD19 sustains the malignant B-cell 
phenotype via mechanisms of proliferation, cell survival and self-renewal [24].  
Blinatumomab is a bi-specific CD19-directed CD3 T-cell engager (BITE) facilitating 
the activation of endogenous T cells when bound to the CD19 expressing target cell 
regardless of the T cell receptor specificity or reliance on major histocompatibility 
complex (MHC) class I molecules on the surface of antigen presenting cells for 
activation [24]. This circumvents a known mechanism of resistance to T cell therapies 
through down-regulation of MHC class molecules. Blinatumomab was initially given as 
short IV infusions, but the absence of objective responses and the toxicity profile 
represented by CNS toxicities, CRS and infections, prompted its investigation as 
continuous infusion [24]. Initial phase II studies showing significant response rates in 
heavily pretreated patients led to considerable excitement and a conditional approval by 
the European Medicines Agency (EMA) in 2015 for adult relapsed ALL. A single arm 
phase II adult study in relapsed ALL demonstrated a CR rate of 33% (n=63) and CR 
with partial hematologic recovery (CRh) of 10% (n=18) after two cycles [25]. After a 
median follow up of 8.9 months, 37% of those eighty-one patients achieving CR/CRh 
were alive and in remission.  
Blinatumomab in children has been investigated in thirty-nine patients with refractory 
or relapsed B-ALL as continuous IV infusion for 4 weeks up to 5 cycles [26]. During 
the first two cycles, twelve patients (31%) achieved CR, and of those five had complete 
MRD response. Six out of these twelve patients underwent bone marrow 
transplantation. Median relapse-free survival (RFS) for responding patients was 5.6 
months. Most common severe adverse events (AEs) were anemia, pyrexia, increased 
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ALT/AST and febrile neutropenia. Grade 3 CRS was reported in two patients (5%). In 
Europe, a phase III trial (NCT02393859) will randomize high-risk relapsed B-cell ALL 
patients to receive blinatumomab or a conventional chemotherapy consolidation block 
before transplantation in a first step. In the adaptive phase of the study, patients will be 
randomized to receive blinatumomab or three consolidation chemotherapy blocks 
before transplant. In the US a phase III trial (NCT02101853) randomizes high and 
intermediate-risk relapsed B-cell ALL between blinatumomab and conventional 
chemotherapy following induction and low-risk patients between chemotherapy +/- 
blinatumumab following induction.  
Coltuximab Ravtansine (SAR3419) is an anti-CD19 humanized mAB drug conjugate to 
DM4, a potent antimitotic agent. Coltuximab is active in pediatric models of B-ALL 
and infant mixed lineage leukemia (MLL) including chemo resistant Ph+ ALL [27]. In 
the phase I-II study of coltuximab single agent in relapsed B-ALL thirty-six adult 
patients were treated with manageable toxicities [28]. The recommended phase II dose 
(RP2D) was 70mg/m2 given IV once weekly for 8 weeks.   
Denintuzumab Mafodotin (SGN-CD19A) is a novel antibody-drug conjugate (ADC) 
composed of a humanized anti-CD19 mAb conjugated to the microtubule-disrupting 
agent monomethyl auristatin F (MMAF), which binds to tubulin and induces G2/M 
arrest and apoptosis [29]. In the phase I study of denintuzumab single agent in relapsed 
B-ALL seventy-one adult patients participated [30]. Maximum tolerated dose (MTD) 
was 5mg/kg every 3 weeks and the MTD was not reached with the weekly dosing.  The 
combined CR rate was 19% for the weekly dosing and 35% for the 3-weekly. AEs were 
similar with both schemas: gastrointestinal, ocular and hematological. The promising 
results in the Ph+ group have prompted an expansion cohort on the 3-weekly dosing.  
 
12 
 
2.4 CD22 directed therapy  
CD 22 is expressed in more than 95% of B-cell ALL in children [31]. CD22 shifts from 
the cytoplasmic domain in developing B cells to the cell surface in later stages of B-Cell 
development.  
Epratuzumab, a humanized anti-CD22 mAb, is internalized after binding to cell surface 
CD22 and modulates B-cell activation and signaling [32]. In the phase II COG study in 
ALL relapsed patients, epratuzumab was given once  (B1) or twice weekly (B2) for a 
total of 4 or 8 doses during block 1 of re-induction [33]. CR rates after block 1 were 
similar for both cohorts and with the AALL01P2 study, a trial using the same 
chemotherapy (B1: 65%; B2: 66%; AALL01P2: 74%). Rates of MRD negativity were 
higher in this phase II study when compared with AALL01P2 (39% Vs 25%), results 
that should be interpreted with caution given the methodological difficulties of using 
historical controls. Early relapsed patients treated in cohort B2 had significant superior 
2-year EFS when compared to AALL01P2 study (54.6% Vs. 25.7%,). IntReALL 2010 
investigates the value of adding epratuzumab from induction to consolidation in a 
randomized fashion to two different regimens, the modified protocol ALL-REZ BFM 
2002 and the UK ALL-R3 in standard risk relapsed ALL patients (NCT01802814).  
Inotuzumab ozogamicin is a humanized mAb directed at CD22 that conjugates the 
moAb with calicheamicin, an antitumor antibiotic. A phase I-II study evaluated two 
different schedules in relapsed/refractory ALL including children [34]. The overall 
response rate was 58% and the CR rate was 19%. A total of 40% of patients could 
undergo transplantation afterwards. In adults with relapsed ALL, inotuzumab single 
agent was challenged against three standard relapse regimens. The CR rate was 
significantly higher with inotuzumab (80.7% Vs 29.4%) and more patients receiving 
inotuzumab had results below the MRD threshold (78.4% Vs 28.1%) [35]. Most 
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frequent toxicity was veno-occlusive disease (VOD). An ITCC phase I-II study 
evaluating inotuzumab in children with refractory/relapsed ALL is launching this year 
in Europe (EudraCT 2016-000227-71).  
Moxetumumab pasudotox is a recombinant immunoconjugate composed of an anti-
CD22 immunoglobulin variable domain genetically fused to a truncated form of 
Pseudomonas exotoxin [36]. A phase I trial single agent in children and young adults 
with relapsed CD22+ hematological malignancies was associated with an acceptable 
toxicity profile (mainly hepatic). Objective responses were achieved in eleven patients 
(30%) including 9 (24%) CR [36]. A recent phase II study in pediatric relapsed ALL 
and LL has been early terminated because the required efficacy for the study 
continuation was not met (NCT02227108). Possible explanations for this limited 
activity are that higher doses are likely required to achieve maximal benefit and that 
drug exposure may be limited to rapid clearance [37]. To overcome these limitations, 
less immunogenic formulations that can be given at higher doses [38] and the 
combination with protein kinases enhancing its activity [39] are investigated.  
 
2.5  CD33 directed therapy 
The CD33 cell surface antigen is present in more than 80% of patients with AML [40]. 
Gemtuzumab-ozogamicin (GO) is a humanized anti-CD33 antibody linked to the DNA-
binding cytotoxin calicheamicin. Single agent activity was seen in a pediatric phase I 
study for relapsed AML with CR rates of 28% [41]. De novo AML children enrolled in 
the phase III COG trial AAML0531 were randomly assigned to receive or not GO 
during induction and consolidation [42]. Three-year EFS was significantly better in the 
GO group (53.1% Vs 46.9%) but there was not significant effect on OS (69.4% Vs 
65.4%). FLT3/Internal Tandem Duplication (ITD)-positive de novo AML pediatric 
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patients treated with GO and conventional chemotherapy and HSCT in first remission 
experienced less relapses in two consecutive COG trials [43]. GO may also have a role 
in the post-transplant setting as a consolidation regimen for those patients with AML, 
where its use has proved to be safe [44] and it is now investigated in a larger population 
(NCT02117297) where GO is given from day 60 to 180 post-transplant. In adults the 
addition of GO to daunorubicin and cytarabine resulted in a significantly higher fatal 
induction toxicity rate (mainly hemorrhages, VOD and other G4 non-hematological 
toxicities) [45]. This prompted its withdrawal from the US market in 2010 [46]. 
Nonetheless, the interest for GO has been revived in AML after two large trials in 
newly diagnosed adult AML showed improvements in OS [47, 48]. An international 
phase III trial will randomize newly diagnosed AML pediatric patients to receive or not 
GO with conventional chemotherapy (NCT02724163). The key point is to find a 
balance between toxicity and efficacy. Low doses of 3mg/m2 can have anti-leukemic 
effect and less undesirable side effects [49].    
In acute promyelocytic leukemia  (APL) CD33 is expressed in virtually 100% of APL 
cells and GO has been better tolerated than conventional chemotherapy, particularly in 
older patients [50]. GO is currently under investigation in newly diagnosed APL in 
combination with ATRA and arsenic trioxide (NCT01409161).  
SGN-CD33A is a novel ADC with a similar antileukemic activity to that of GO but 
without liver toxicity [51]. AMG 330 is a T-specific-cell-engaging antibody with dual 
specificity for CD3/CD33 that has shown promising activity in preclinical models and 
has now entered first in human clinical trials [52].  
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3 BCR-ABL inhibitors 
The introduction of the TKI imatinib in front-line Ph+ ALL pediatric protocols radically 
changed the prognosis of these patients. Continuous use of imatinib along with 
conventional chemotherapy has improved the EFS of these patients from 29% to 81% 
[53]. In the COG-ALLL0031 study, the positive impact of continuous imatinib persisted 
regardless of the whether these patients were treated only with chemotherapy or 
received an allogeneic transplant [54]. A major drawback is the appearance of 
resistance, often through the development of point mutations in the ABL tyrosine kinase 
domain (ABL-TKD) [55]. Second generation TKI such as dasatinib and nilotinib are 
effective for M244V and H396P mutations [56] but not for T315I; dasatinib has been 
investigated in children with newly diagnosed Ph+ ALL (NCT00720109). Ponatinib is 
highly effective in T315I mutated Ph+ ALL [57], although severe vascular side effects 
can occur [58]. Pediatric development for ponatinib has not started yet.  
In pediatric CML, TKIs have become the cornerstone of first-line treatment. Children 
with newly diagnosed CML in chronic phase (CP) treated with imatinib 260mg/m2 [59] 
had a 3-year PFS of 98%. The rates of complete cytogenetic response (CCyR) and 
major molecular response (MMR) were 77% and 57% during follow up.  
In the ITCC phase I study of dasatinib, of the 17 patients with CML-CP, 94% had a 
CHR, 88% major cytogenetic response (MCyR) and 82% CCyR [60]. PFS and OS at 
two years were 61% and 88%. The RP2D in children with CP-CML was 60mg/m2 OD 
and 80mg/m2 for those with accelerated phase (AP)/blastic phase (BP)-CML or Ph+ 
ALL. The pediatric study with nilotinib for children with newly diagnosed and resistant 
or intolerant to imatinib/dasatinib CML has recently completed recruitment 
(NCT01844765). An ITCC phase I/II study evaluating bosutinib in pediatric patients 
with refractory/relapsed or intolerant to TKIs CML is launching this year in Europe 
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(Netherlands trial registry number: NTR5501). Most frequent toxicities are 
hematological. Non-hematological toxicities are rash, edema, hepatic, myalgia, bone 
pain, growth retardation and QT prolongation [59–61].  
 
4 Small molecule inhibitors of intracellular kinases 
This section will cover agents targeting intracellular signaling pathways mediated by 
kinases activated in leukemic cells or that form part of the cell cycle. 
 
4.2  JAK/STAT 
The JAK family of tyrosine kinases activates the STAT family of transcription factors. 
The JAK/STAT pathway mediates cytokine receptor-derived signals and plays a role in 
hematopoietic cell growth, proliferation, differentiation and survival [62]. 
In a series of fifty-three Down´s syndrome associated ALL (DS-ALL) patients, all ten 
patients with JAKR683 somatic mutations had CRLF2 aberrant expression [63]. 
Therapies blocking the CRFL2/JAK2 pathways are an attractive approach in these 
patients.  
In a series of pediatric T-cell ALL, 45% had mutations in IL7Ra, JAK, RAS, AKT and 
PTEN and occurred in a mutually exclusive fashion suggesting that they share aberrant 
activation of similar downstream targets [64]. IL7Ra and JAK mutants were relatively 
resistant to downstream RAS-MEK-ERK or PI3K-AKT-mTOR inhibition, suggesting 
that a combined synergistically inhibition can be of interest.  
In children with Ph-like ALL, genetic alterations and rearrangements in CRLF2, JAK-
STAT, ABL1 and PDFGRB have been frequently observed, with up to 50% in the case 
of CRLF2 rearrangements [65].  
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In the phase I trial of the JAK inhibitor ruxolitinib in children with relapsed cancers the 
RP2D was 50mg/m2 orally BID continuously [66] but no responses were seen in 
patients with leukemia. Only one patient with polycythemia vera achieved partial 
response. There were not JAK aberrant cases. The inhibition of phosphoproteins JAK2, 
STAT5 and S6 was not dose dependent. Most frequent toxicities were hematological 
and gastrointestinal.  
A COG phase II study is now evaluating ruxolitinib in combination with chemotherapy 
in newly diagnosed high-risk Ph-like B-ALL patients (NCT02723994). 
 
4.3  Ras/Raf/MEK/ERK 
The mitogen-activated protein kinase (MAPK) cascade regulates cell proliferation and 
survival [67] and generates signal output through other effector pathways such as 
PI3K/AKT/mTOR and RalGEF/RAL [68]. Involved mechanisms in the activation of 
the Ras pathway include somatic mutations in upstream activators or regulatory proteins 
(NRAS, KRAS, BRAF, FLT3, PTPN11, CBL or NF1) and the incidence of these 
mutations in newly diagnosed ALL is up to 35% and 39% in relapsed patients [68]. In a 
series of 206 relapsed ALL patients, RAS mutant positive patients had a higher 
proportion of early relapses and shorter median time to relapse compared with wild type 
(WT) patients [69].  RAS mutations are an independent predictor for poor outcome in 
MLL rearranged infant ALL[70] 
Due to the difficulties in developing direct inhibitors of the RAS protein itself, efforts 
have focused on disrupting RAS post-translational processing. In this sense, tipifarnib, 
an orally bioavailable farnesyltransferase inhibitor, was tested in a phase I study 
including children with refractory leukemias [71]. The RP2D was established at 
300mg/m2 BID for 21 days of a 28-day cycle. No responses were seen in ALL patients 
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and only one patient with JMML experienced stable disease (SD). Toxicities were 
mainly cutaneous and gastrointestinal.  
MEK inhibition is an attractive approach in pediatric ALL, as it may be capable to 
inhibit the pathway regardless of the mechanism of upstream activation. The frequency 
of mutations in the RAS/RAF/MEK pathway is higher in prednisolone-resistant ALL-
children [72]. A complete sensitization to prednisolone after trametinib was observed in 
pediatric ALL cell lines, suggesting that MEK inhibition may modulate prednisolone 
resistance and improve clinical outcome of childhood B-ALL [72]. Selumetinib induced 
dramatic reduction in leukemia cells in mice with implanted RAS mutant ALL [69]. 
Single agent activity was modest in untreated adult AML, but with favorable toxicity 
profile, suggesting its potential role in combination [73].  
 
4.4 FLT3 inhibitors  
Activating mutations of the FLT3 gene have been described in pediatric ALL and AML, 
particularly in those with 11q23/MLL rearrangements [74]. Lestaurtinib, an FLT3 
inhibitor, was found to be highly active in ALL cell lines with MLL gene 
rearrangements, high-hyperdiploidy and FLT3 mutations [75]. An ongoing phase III 
study for infants with newly diagnosed MLL rearranged ALL evaluates the addition of 
lestaurtinib in a randomized fashion to combination chemotherapy (NCT00557193). 
Midostaurin single agent has been evaluated in a phase I/II trial in pediatric patients 
with relapsed/refractory leukemia [76]. The RP2D for combination studies is 30mg/m2 
BID. Five patients with AML and three ALL achieved a modest clinical response. Most 
frequent toxicities were vomiting, pyrexia and thrombocytopenia. Crenolanib is 
currently being investigated in combination with sorafenib in patients with 
relapsed/refractory AML and FLT3-ITD/TKD mutations (NCT02270788). 
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Sorafenib single agent and in combination has demonstrated to be active in pediatric 
AML mutant FLT3/ITD [77]. In the ongoing phase III COG AML trial 
(NCT01371981), high-risk FLT3/ITD+ patients receive sorafenib from induction.   
 
4.5 Polo like kinases  
Polo-Like Kinase 1 (PlK1) is a serine/threonine specific kinase implicated in several 
steps of cell mitosis [78]. Volasertib inhibits PlK1, resulting in cell cycle arrest and 
apoptosis [78]. Pre-clinical activity has been demonstrated in ALL, rhabdomyosarcoma 
(RMS), neuroblastoma and glioblastoma, both as single agent [78] and in RMS with 
chemotherapy [79]. A phase I dose escalation trial in refractory/relapsed pediatric 
tumors has been recently completed (NCT01971476). A phase I trial in children with 
AML after front line failure combines volasertib with chemotherapy (NCT02722135).  
 
5. Proteasome inhibitors 
Proteasome inhibitors have emerged as a one of the most promising therapeutics for 
hematological malignancies, particularly in adult multiple myeloma [80]. Pre-clinical 
studies indicate that malignant cells are more susceptible to their cytotoxic effects than 
normal cells. Several cellular processes contribute to their apoptotic effect: inhibition of 
NFκB activity, altered degradation of cell cycle related proteins, altered pro-apoptotic 
and anti-apoptotic protein balance, endoplasmic reticulum stress and inhibition of 
angiogenesis and DNA repair [80].  
Bortezomib, the first proteasome inhibitor authorized for multiple myeloma in adults, 
demonstrated activity in ALL cell lines and xenografts models [81]. The phase I trial of 
bortezomib with standard induction chemotherapy in children with relapsed ALL [82] 
defined the RP2D was 1.3mg/m2 on days 1, 4, 8 and 11 and 6/10 patients achieved a 
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CR. This schema was evaluated in a phase II study with 22 patients [83] and an 80% 
response rate in B-precursor patients. The COG evaluated the safety of bortezomib in 
combination with either idarubicine/cytarabine or cytarabine/etoposide in a cohort of 
forty-six patients with relapsed AML [84].  The CR rates were 29% and 43% 
respectively. Toxicity is mainly hematological, infection and neuropathy. Toxicity on 
thrombopoiesis from bortezomib has been observed in adults with advance 
hematological malignancies and multiple myeloma [85] that may limit its development 
in certain hematological diseases, which does not seem to be such a frequent event in 
children [83].  
Bortezomib is under investigation in the phase III COG trial for newly diagnosed T-Cell 
ALL and lymphoma (NCT02112916) where patients are randomized to receive it or not 
during induction. In the European phase III BFM study in high-risk first relapsed ALL 
(EudraCT: 2012-000810-12), patients will be randomly assigned to receive or not 
bortezomib during induction. In AML, the phase III COG AML trial (NCT01371981) is 
currently randomizing newly diagnosed low and high-risk patients to receive or not 
bortezomib with combination chemotherapy.  
Carfilzomib, a second-generation proteasome inhibitor, is under investigation in a 
pediatric phase I trial in relapsed ALL with conventional chemotherapy during 
induction (NCT02303821). 
 
6. Epigenetic targeting  
This section will cover drug candidates against epigenetic targets that have been 
described to play a role in pediatric leukemias.  
 
6.1  DOT1L 
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Rearrangements in the MLL gene are present in up to 70% of patients with infant ALL 
[86]. The t(10;11)(p12;q23) and t(10;11)(p12;q14) translocations, which encode 
respectively the MLL-AF10 and CALM fusion proteins, are recurrent chromosomal 
rearrangements observed in acute leukemias [87, 88]. MLL-AF10 and CALM fusion 
proteins interact with histone H3 lysine 79(H3K79)-specific methyltransferase DOT1l. 
Although DOT1L has not been found to be genetically altered in leukemia [89], the 
interaction of these and others MLL-fusion proteins with DOT1L can lead to the 
mistargeting of DOT1L and subsequent methylation of H3K79, favoring leukemogenic 
transformation [90, 91]. EPZ5676 (pinometostat), a small molecule inhibitor of DOT1L 
H3K79 methyltransferase activity, has shown activity in cell lines bearing MLL-AF9, 
MLL-AF4, and MLL-ENL fusions [92]. A phase I trial investigating EPZ5676 single 
agent in pediatric patients with relapsed leukemia harboring rearrangements of the MLL 
gene has included eleven patients [93], showing similar PK profiles between adults and 
children. No responses were observed.  
Besides this, the BCL-2 anti-apoptotic proteins are utilized by the lymphoid 
malignancies to maintain viability under conditions of oncogenic stress [94]. 
Chromatin-sequencing studies have shown that MLL/AF4 up-regulates the BCL-2 gene 
but not other BCL-2 family members via DOT1L-mediated H3K79me2/3 [95]. The 
combination of ABT-199, a BCL-2 inhibitor, with DOT1L inhibitors (SGC0946 and 
EPZ5676) showed deep growth inhibition in t(4;11) cells ; a synergistic effect was also 
demonstrated when ABT-199 was combined with chemotherapy [95]. Targeting BCL-2 
is an attractive approach for multiple hematological malignancies [96] and therefore 
ABT-199 is now being investigated in adult CLL, AML and other non-Hodgkin 
lymphomas.  
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6.2  Hypomethylating agents (DNMT) 
DNA methyltransferase (DNMT)-inhibiting cytosine nucleoside analogues reduce 
methylation from promoter regulatory regions of tumor suppressor genes silenced by 
DNA methylation, which reactivates cell growth arrest and differentiation [97].  
Azacitidine (AzaC) and decitabine have been effectively used in the treatment of adult 
AML [98].  
In children, AzaC has been used in newly diagnosed and relapsed myelodisplastic 
syndrome (MDS) and JMML with promising and durable responses allowing patients 
entering HSCT in some cases [99, 100]. Two phase II clinical trials are evaluating AzaC 
in children with newly diagnosed and relapsed MDS and JMML (NCT02447666 and 
EudraCT 2010-022235-10).  
In pediatric AML, AzaC in combination with amsacrine and etoposide was active in 
refractory patients with AML, with a CR rate of 53% [101]. Decitabine has been 
evaluated as single agent as well as in combination with cytarabine but is not being 
taken forward into larger pediatric studies.  
 
6.3  HDAC 
Histone deacetylase (HDAC) inhibitors enhance histone acetylation leading to 
transcriptional repression and epigenetic silencing [102].  HDAC activity is increased in 
pediatric ALL and AML [103]. The use of HDAC inhibitors in MLL-rearranged ALL 
has been shown effective [104]. Vorinostat was evaluated in a phase I study in children 
with refractory tumors [105]. No responses were observed in the cohort of 
hematological malignancies. Vorinostat is currently under investigation in combination 
with chemotherapy and bortezomib for MLL-rearranged pediatric leukemias 
(NCT02419755). In ALL cell lines, vorinostat reprogramed the aberrant gene 
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expression profile of relapsed blasts and the incorporation of decitabine led to 
reexpression of genes methylated and silenced at relapse [106]. These two drugs 
followed in combination with conventional chemotherapy have been applied in a pilot 
study including eight children [107]. Overall response rate was 46.2% and five patients 
could be transplanted. A TACL phase I trial of panobinostat single agent in pediatric 
patients with relapsed ALL and AML has been recently completed (NCT01321346). 
 
7. Future directions  
Over the last two years, major advances in the field of immunotherapy, mainly with the 
development of immune checkpoint inhibitors have occurred in several adult solid 
tumors including melanoma and lung cancer. Anti-PD-1 and anti-PD-L1agents are 
showing promising results in adult leukemia and lymphoma trials and there is great 
interest in the pediatric community to evaluate this class of agents in childhood 
leukemia and lymphoma.  
CAR-T cell therapy has demonstrated to be very effective in early studies in relapsed 
ALL, particularly in a fragile population where most patients had already undergone 
multiple treatment lines including allogeneic transplantation. After its approval for 
adults, blinatumomab has now entered phase III trials in first relapse pediatric high-risk 
B-ALL to test whether it may substitute conventional chemotherapy and serve as a less 
toxic bridge for transplantation. Inotuzumab single agent has been shown to be 
significantly more effective than other standard regimens for relapsed ALL in adults, 
and a pure pediatric trial is launching this year in Europe.  
New BCR-ABL inhibitors are due to overcome the limitations on inherent or acquired 
resistance and toxicity when used in a prolonged fashion. Ponatinib is the first TKI 
demonstrating to be effective in T315I mutant Ph+ ALL, although its potential serious 
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vascular associated events in children are a concern, lower doses may counteract for a 
better safety profile and bosutinib is expected to have a better safety profile. 
FLT3 inhibition is a promising approach in MLL and FLT3-driven leukemias, a 
necessary driver of leukemogenesis particularly in infants. FLT3 inhibitors have a 
manageable toxicity profile and its capacity to be combined with already effective 
chemotherapeutics makes them very attractive. The addition of lestaurtinib to 
conventional chemotherapy in infants with ALL has already been investigated, and 
results still waited. Sorafenib is under investigation in newly diagnosed AML mutant 
FLT3/ITD.  
Proteasome inhibitors are also well advanced in their development. Bortezomib has 
reached phase III trials in newly diagnosed ALL. The addition of these agents to already 
intensive and toxic induction to remission regimens remains a concern and future 
strategies need to take into consideration this premise.  
 
8. Conclusions 
The impressive improvement in survival rates in pediatric leukemia, particularly ALL, 
between the early 60´s and 90´s is the most representative successful story in pediatric 
cancer. There has been no parallel before that or since then, notably because it has been 
achieved by using almost the same conventional chemotherapeutics that were available 
half a century ago. Our goal now is to continue improving these survival figures while 
minimizing the undesirable side effects of conventional treatment. New targeted 
therapies will truly contribute to this objective.  
Integrating these novel agents into existing chemotherapy regimens and managing the 
additive side effects in an otherwise fragile population is complex. We have definitely 
entered into a new and fascinating era. Unveiling cancer genetics and discovering the 
mechanisms of escape of tumor cells opens the door to a more adapted therapy that will 
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lead to improved outcomes for these patients.  
 
9. Expert opinion 
The development of new agents in pediatric leukemia and its incorporation into clinical 
practice remains challenging.  
Key challenges and barriers are well known and, while not discussed in detail in this 
review, they are being addressed by academic researchers and collaborative studies. 
Mainly, these comprise: i) Pediatric research platforms are necessary to identify 
molecular targets and to evaluate new agents by means of a comprehensive and 
meaningful pre-clinical testing that selects promising agents to be developed into 
clinical practice; ii) A close collaboration between industry and academic groups is 
essential to implement these findings into clinical practice; iii) Molecular screening at 
the time of relapse by means of high-throughput technologies may be able to identify 
molecular targets in particular patients that potentially can benefit from more directed 
approaches, rather than exposing patients to drugs that will not derive any benefit if the 
molecular abnormality is not present; iv) Combinations of biological agents are being 
tested to identify possible synergies and to overcome potential escape mechanisms; v)  
Improvements in incentives for those drugs and targets specific of pediatric cancers and 
vi) Switching pediatric drug development from a model centered on adult conditions to 
another more based on the mechanism of action [108]. ALL and AML comprise the 
majority of pediatric leukemias and will most likely need different developmental 
pathways. While the pediatric AML field might benefit from biological similarities 
between adult and pediatric AML, pediatric and adult ALL represent different entities 
and will need different pre-clinical and clinical studies.   
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Despite these challenges not overcome yet, we have witnessed major progress over the 
past five years thanks to the completion of sequencing studies at diagnosis and relapse, 
identification of new targets such as epigenetics, and numerous agents being tested 
preclinically. Thus, promising targets and drugs have been identified and these have 
been taken forward into pediatric early clinical trials in leukemia. Conducting these 
trials is demanding in a frail population with multiply relapsed leukemia and have 
required major efforts from cooperative groups in both sides of the Atlantic. Despite no 
drugs reaching regulatory approval for pediatric indications with the exception of 
imatinib, still the number of drugs entering the clinic and those transitioning from early 
to late phase clinical trials has significantly increased in recent years. Moreover, a better 
understanding of cancer biology, recurrent genomic aberrations and mechanisms of 
disease has led to more robust preclinical “proof-of-concept” data packages supporting 
clinical development of agents for pediatric leukemia.  
As shown in this manuscript, the number of agents that have been tested in early trials 
in pediatrics is quite significant, with very few of them showing convincing positive 
results leading to fast-tracked development into larger studies and frontline use. In this 
sense, agents in early trials have been developed against most hallmarks of cancer, 
hence exploiting all possible vulnerabilities of leukemic cells, their microenvironment 
and immune response in order to maximize the efficacy of new drugs and combinations. 
Among those, agents targeting cell surface antigens, intracellular signaling pathways 
and cell cycle inhibitors or epigenetic regulators are most prominent. Additionally, 
major advances have occurred thanks to new developments in engineering leading to 
optimized molecules such as BITEs, antibody-drug conjugates or CAR-T cells with 
improved pharmacological and immunological properties. In this sense, agents holding 
most promise comprise some targeted agents that have had outstanding results in early 
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trials such as CAR-T cells or BITEs that remain to be confirmed in larger studies and 
other drugs that have already reached frontline or randomized clinical trials such as 
bortezomib or gentuzumab ozogamycin. 
In summary, having identified the challenges and established the basis for more 
efficient preclinical and clinical drug development for pediatric leukemias, numerous 
agents are moving ahead in its development for pediatric leukemia and it is hoped that 
new drugs will reach clinical practice in coming years.  
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Table footnotes 
Table 1. Active and near future clinical trials with novel agents in pediatric leukemia 
Footnotes:  
ALL: Acute lymphoblastic leukemia; AML: Acute myeloid leukemia; APL: Acute 
promyelocytic leukemia; ATO: Arsenic trioxide; ATRA: All-trans retinoic acid; BFM: 
Berlin-Frankfurt-Munich BLe: Burkitt leukemia; BLy: Burkitt lymphoma; CARs: 
Chimeric antigen receptors; CML: Chronic myeloid leukemia; CT: Chemotherapy; GO: 
Gemtuzumab-ozogamicin; DNMT: DNA methyltransferase; HDAC: Histone 
deacetylase; HR: High-risk; IP: Investigational product; IR: Intermediate-risk; ITD: 
Internal tandem duplication; JMML: Juvenile myelomonocytic leukemia; LL: 
Lymphoblastic lymphoma; LR: Low-risk; MDS: Myelodysplastic syndrome; MLLr: 
Mixed lineage leukemia rearranged; SR: Standard-risk; TKD: Tyrosine-kinase domain; 
TKIs: Tyrosine-kinase inhibitors; UK: United Kingdom; VSLI: vincristine sulfate 
liposome injection.  
* These two studies are part of the same trial (NCT01371981) 
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Figures footnotes 
Figure 1. Mode of action of selected drugs for discussion 
In bold, agents that have reached phase III trials or are considered highest priority for 
development.  
HDAC: Histone deacetylase  
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Figure 2. Current degree of development of selected drugs for discussion. 
Most representative and advanced agents from each therapeutic group discussed in the 
manuscript are presented according to their respective degree of development. Top 
priority agents are highlighted in bold.  
ALL: Acute lymphoblastic leukemia; AML: Acute myeloid leukemia; BITE: b-specific 
T-cell engager; CML: Chronic myeloid leukemia; HDAC: Histone deacetylase; ITD: 
Internal tandem duplication; LL: Lymphoblastic leukemia; MDS: Myelodisplastic 
syndrome; JMML: Juvenile myelomonocytic leukemia.  
* Registration for pediatric indication 
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Table 1. Active and near future clinical trials with novel agents in pediatric leukemia 
Compound Target Indication Intervention Population Phase Reference 
Chimeric antigen receptors directed therapy (CARs) 
CAR-T cells CD19 Relapsed B-Cell ALL Single agent 
Up to 17 
years 
II 
EudraCT: 2013-
003205-25 
CAR-T cells CD19 
Relapsed B-Cell 
malignancy 
Single agent 1-30 years I/II NCT02772198 
CAR-T cells CD22 
Relapsed B-
ALL/Lymphoma 
Single agent 1-30 years I NCT02315612 
Cell surface antigens: Immune strategies 
Ofatumumab CD20 
First or second line B-
ALL/LL 
Obinotuzumab + BFM augmented therapy 12-30 years II NCT02419469 
Blinatumumab CD19 
HR First Relapse B-
ALL 
Randomization between blinatumumab or consolidation CT 
Up to 17 
years 
III NCT02393859 
Blinatumumab CD19 
LR, IR, HR Relapse B-
ALL 
 
IR and HR: Randomization between blinatumumab or consolidation 
CT 
LR: Randomization between backbone CT ± blinatumumab 
1-30 years III NCT02101853 
Denintuzumab CD19 
Relapsed B-ALL or 
BLe/BLy 
Single agent: Weekly or three weekly dosing From 1 year I NCT01786096 
Epratuzumab CD22 
SR First Relapse B/T-
ALL 
Randomization between backbone BFM or UK-ALL R3 CT ± 
epratuzumab 
Up to 17 
years 
III NCT01802814 
Inotuzumab CD22 Relapsed B-ALL Single agent 
Up to 17 
years 
I/II 
Launching 
2016 
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Gemtuzumab CD33 Newly diagnosed AML Randomization between backbone AML CT ± gemtuzumab 
Up to 17 
years 
III NCT02724163 
Gemtuzumab CD33 AML/MDS 
Post-transplant consolidation GO single agent between day 60 and 
180 
Up to 30 
years 
II NCT02117297 
Gemtuzumab CD33 Newly diagnosed APL Single arm: GO + ATRA + ATO 
From 10 
years 
II NCT01409161 
BCR-ABL inhibition  
Bosutinib - 
Relapsed/Refractory 
CML or intolerant to 
TKIs 
Single agent bosutinib 
Up to 17 
years 
I NTR5501 
Small molecules inhibitors of intracellular kinases 
Ruxolitinib Jak/Stat 
Newly diagnosed HR 
Ph-like B-ALL 
Single arm: Backbone induction CT + ruxolitinib 1-21 years II NCT02723994 
Ruxolitinib / 
Dasatinib 
Jak/Stat 
Relapsed Ph-Like B-
ALL 
3-week window single agent followed by Hyper-CVAD + IP 
From 10 
years 
II NCT02420717 
Selumetinib Ras/Raf/Mek/Erk Relapsed ALL Single arm: Selumetinib and dexamethasone 
To be 
confirmed 
I ECMC 
Sorafenib FLT3 
Newly diagnosed HR 
FLT3/ITD + AML 
Single arm: Backbone AML CT + sorafenib 
Up to 29 
years 
III NCT01371981* 
Crenolanib FLT3 
Relapsed hematological 
malignancies FLT3-ITD, 
TKD mutated 
Single arm: Crenolanib and sorafenib 1-39 years I NCT02270788 
Volasertib Polo-Like Relapsed AML Single arm: Backbone CT + Volasertib 
3 months-17 
y 
I NCT02722135 
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Proteasome inhibitors 
Bortezomib - 
Newly diagnosed T-
ALL/LL 
Randomization between backbone ALL CT ± bortezomib during 
induction 
2-30 years III NCT02112916 
Bortezomib - 
HR First Relapse B-
ALL 
Randomization between backbone BFM CT ± bortezomib during 
induction 
Up to 18 
years 
III 
EudraCT: 2012-
000810-12 
Bortezomib -  Newly diagnosed AML 
Randomization between backbone AML CT ± bortezomib during 
induction 
Up to 29 
years 
III NCT01371981* 
Carfilzomib - Relapsed B-ALL Single arm: UK R3 Induction backbone CT + carfilzomib 
Up to 18 
years 
I/II NCT02303821 
Epigenetic targeting 
EPZ5676 DOT1L Relapsed AML/ALL Single agent EPZ5676 
3 months-18 
y 
I NCT02141828 
Azacitidine DNMT 
Newly diagnosed 
MDS/JMML 
Single agent azacitidine 1 month-18 y II NCT02447666 
Decitabine DNMT Relapsed AML Single arm: Cytarabine + decitabine 1 month-18 y I/II NCT01853228 
Vorinostat HDAC 
Relapsed MLLr 
leukemia 
Single arm:  Backbone CT + vorinostat + bortezomib 
Up to 21 
years 
II NCT02419755 
Panobinostat HDAC Relapsed AML/MDS Single arm: Panobinostat + fludarabine + cytarabine 
Up to 24 
years 
I NCT02676323 
Panobinostat HDAC 
Relapsed/Refractory 
ALL/LL 
Single arm: Backbone CT  + Panobinostat + bortezomib + VSLI 
Up to 21 
years 
II NCT02518750 
 
ALL: Acute lymphoblastic leukemia; AML: Acute myeloid leukemia; APL: Acute promyelocytic leukemia; ATO: Arsenic trioxide; ATRA: All-
trans retinoic acid; BFM: Berlin-Frankfurt-Munich BLe: Burkitt leukemia; BLy: Burkitt lymphoma; CARs: Chimeric antigen receptors; CML: 
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Chronic myeloid leukemia; CT: Chemotherapy; GO: Gemtuzumab-ozogamicin; DNMT: DNA methyltransferase; ECMC: Experimental Cancer 
Medicine Centre; HDAC: Histone deacetylase; HR: High-risk; IP: Investigational product; IR: Intermediate-risk; ITD: Internal tandem 
duplication; JMML: Juvenile myelomonocytic leukemia; LL: Lymphoblastic lymphoma; LR: Low-risk; MDS: Myelodysplastic syndrome; 
MLLr: Mixed lineage leukemia rearranged; SR: Standard-risk; TKD: Tyrosine-kinase domain; TKIs: Tyrosine-kinase inhibitors; UK: United 
Kingdom; VSLI: vincristine sulfate liposome injection.  
* These two studies are part of the same trial (NCT01371981) 
 
